Jul 14 2026
 Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Posted at Jul 14 2026
h in News by

INDIANAPOLIS, June 24, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.

Check out the full article here.

Print page